These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 31870139)

  • 1. Knowledge and Viewpoints on Biosimilar Monoclonal Antibodies among Asian Physicians: Comparison with European Physicians.
    Park SK; Moon W; Kim ES; Park SH; Park DI
    Korean J Gastroenterol; 2019 Dec; 74(6):333-340. PubMed ID: 31870139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Viewpoint: knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohn's and Colitis Organization.
    Danese S; Fiorino G; Michetti P
    J Crohns Colitis; 2014 Nov; 8(11):1548-50. PubMed ID: 25008477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in Biosimilar Knowledge among European Crohn's Colitis Organization [ECCO] Members: An Updated Survey.
    Danese S; Fiorino G; Michetti P
    J Crohns Colitis; 2016 Nov; 10(11):1362-1365. PubMed ID: 27112706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment preferences of originator versus biosimilar drugs in Crohn's disease; discrete choice experiment among gastroenterologists.
    Baji P; Gulácsi L; Lovász BD; Golovics PA; Brodszky V; Péntek M; Rencz F; Lakatos PL
    Scand J Gastroenterol; 2016 Jan; 51(1):22-7. PubMed ID: 26059967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recommendations on TNFα inhibitor biosimilar use in clinical practice: a comparison of European gastroenterology IBD guidance.
    Meijboom RW; Barbier L; Druedahl LC; Sarnola K; Tolonen HM; Gardarsdottir H; Egberts TCG; Giezen TJ
    Expert Opin Biol Ther; 2023; 23(8):801-817. PubMed ID: 36947408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biosimilars: The viewpoint of Italian patients with inflammatory bowel disease.
    Macaluso FS; Leone S; Previtali E; Ventimiglia M; Armuzzi A; Orlando A;
    Dig Liver Dis; 2020 Nov; 52(11):1304-1309. PubMed ID: 32807691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy, Safety and Immunogenicity of Biosimilars in Inflammatory Bowel Diseases: A Systematic Review.
    Martelli L; Peyrin-Biroulet L
    Curr Med Chem; 2019; 26(2):270-279. PubMed ID: 27758715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Biosimilars in Inflammatory Bowel Disease (IBD): Experiences and perceptions of german gastroenterologists].
    Bokemeyer B; Dignaß A; Schreiber S
    Z Gastroenterol; 2017 Apr; 55(4):369-374. PubMed ID: 28056484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing gastroenterologist and patient acceptance of biosimilars in ulcerative colitis and Crohn's disease across Germany.
    Sullivan E; Piercy J; Waller J; Black CM; Kachroo S
    PLoS One; 2017; 12(4):e0175826. PubMed ID: 28410403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biosimilar Infliximab in Inflammatory Bowel Disease: Outcomes of a Managed Switching Programme.
    Razanskaite V; Bettey M; Downey L; Wright J; Callaghan J; Rush M; Whiteoak S; Ker S; Perry K; Underhill C; Efrem E; Ahmed I; Cummings F
    J Crohns Colitis; 2017 Jun; 11(6):690-696. PubMed ID: 28130330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases.
    Papamichael K; Van Stappen T; Jairath V; Gecse K; Khanna R; D'Haens G; Vermeire S; Gils A; Feagan BG; Levesque BG; Vande Casteele N
    Aliment Pharmacol Ther; 2015 Nov; 42(10):1158-69. PubMed ID: 26365281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perceived Risks Contra Benefits of Using Biosimilar Drugs in Ulcerative Colitis: Discrete Choice Experiment among Gastroenterologists.
    Baji P; Gulácsi L; Golovics PA; Lovász BD; Péntek M; Brodszky V; Rencz F; Lakatos PL
    Value Health Reg Issues; 2016 Sep; 10():85-90. PubMed ID: 27881284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Experience with Biosimilars of Infliximab in Inflammatory Bowel Disease.
    Avila-Ribeiro P; Fiorino G; Danese S
    Curr Pharm Des; 2017; 23(44):6759-6769. PubMed ID: 29205114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD).
    Fiorino G; Caprioli F; Daperno M; Mocciaro F; Principi M; Viscido A; Fantini MC; Orlando A; Papi C; Annese V; Danese S; Vecchi M; Rizzello F; Armuzzi A;
    Dig Liver Dis; 2019 May; 51(5):632-639. PubMed ID: 30872085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progress with infliximab biosimilars for inflammatory bowel disease.
    Kurti Z; Gonczi L; Lakatos PL
    Expert Opin Biol Ther; 2018 Jun; 18(6):633-640. PubMed ID: 29688797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in inflammatory bowel disease patients' perspectives on biosimilars: A follow-up survey.
    Peyrin-Biroulet L; Lönnfors S; Avedano L; Danese S
    United European Gastroenterol J; 2019 Dec; 7(10):1345-1352. PubMed ID: 31839960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient Perspectives on Biosimilars: A Survey by the European Federation of Crohn's and Ulcerative Colitis Associations.
    Peyrin-Biroulet L; Lönnfors S; Roblin X; Danese S; Avedano L
    J Crohns Colitis; 2017 Jan; 11(1):128-133. PubMed ID: 27481878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of a medical interview on the decision to switch from originator infliximab to its biosimilar in patients with inflammatory bowel disease.
    Haghnejad V; Le Berre C; Dominique Y; Zallot C; Guillemin F; Peyrin-Biroulet L
    Dig Liver Dis; 2020 Mar; 52(3):281-288. PubMed ID: 31648920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial.
    Strik AS; van de Vrie W; Bloemsaat-Minekus JPJ; Nurmohamed M; Bossuyt PJJ; Bodelier A; Rispens T; van Megen YJB; D'Haens GR;
    Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):404-412. PubMed ID: 29606564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biosimilars of adalimumab: the upcoming challenge in IBD.
    Fiorino G; Gilardi D; Correale C; Furfaro F; Roda G; Loy L; Argollo M; Allocca M; Peyrin-Biroulet L; Danese S
    Expert Opin Biol Ther; 2019 Oct; 19(10):1023-1030. PubMed ID: 30601098
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.